What people actually say about Recursion Pharmaceuticals
19 mentions across 1 sources · 42% positive · researched Oct 15, 2026
YouTube
What users praise
- • REC-1245 Phase 1 data showed well-tolerated safety and predictable pharmacokinetics with no DLTs observed
- • Clinical-stage pipeline gives the AI platform narrative concrete, checkable evidence points
- • Genentech optioned the first neuroscience target in August 2026, validating the partnership model
What frustrates them
- • Community discussion is almost entirely about the stock, not the platform or its scientific merit
- • Retail shareholders repeatedly flag huge outstanding share count and ongoing executive selling
- • No licensable product means outside researchers and developers cannot evaluate the AI stack
This is a summary. The full report adds every quote we found, a per-source breakdown, recurring themes, hidden costs and the learning curve — run a free scan below, or see the full Recursion Pharmaceuticals review.
What comes up again and again about Recursion Pharmaceuticals
Recurring themes across everything we collected, with where each one showed up.
The stock's financials — dilution, insider selling, and executive compensation — dominate the conversation far more than the science
criticised · seen on YouTube
Short-seller influencer content (especially Martin Shkreli's video) is driving the bearish narrative, and commenters accuse it of being self-promotional
mixed · seen on YouTube
Bulls anchor on REC-4881 for FAP as a potential near-term catalyst with real physician enthusiasm
praised · seen on YouTube
Clean REC-1245 Phase 1 safety data (no DLTs) is cited as evidence the AI platform is producing viable candidates
praised · seen on YouTube
Retail investors see quiet accumulation in the stock despite the bearish narrative, reading it as institutional interest
praised · seen on YouTube
The annual shareholder meeting was widely panned as performative, with complaints about payouts despite poor share performance
criticised · seen on YouTube
How hard is Recursion Pharmaceuticals to learn?
Users describe it as advanced · typically Days of setup to get going
Where people get stuck
- • The platform isn't accessible to outsiders, so there's no 'getting started' as a user
- • Understanding the company requires reading clinical trial data, not just product docs
- • Community signal is buried in stock commentary rather than technical discussion
- • Distinguishing platform claims (50+ PB, 2M experiments/week) from independently verifiable facts
Who Recursion Pharmaceuticals actually suits
Works well for
- • Public-market biotech investors with tolerance for clinical-stage risk and multi-year timelines
- • Pharma and biotech partners evaluating a wet-lab-plus-ML discovery collaboration
- • Analysts tracking the TechBio sector who need to understand Recursion's pipeline catalysts
Not the right fit for
- • Developers or data scientists looking for a licensable AI drug discovery software product
- • Researchers who need to run their own experiments on the platform, since it is internal only
- • Investors seeking near-term revenue or low-volatility exposure
What people are discussing right now
Discussion volume is low and trending down
- Shkreli's short thesis on RXRX and his Godel Terminal promotion
- Share dilution and executive selling
- REC-4881 Phase 2 data anticipation for FAP
- REC-1245 Phase 1 safety results
- Comparisons to earlier failed AI-drug-discovery narratives
What people really think about Recursion Pharmaceuticals
A real-time sweep of the open web — social media, forums, review sites, video reviews and live community discussions — distilled into one honest verdict with the actual mentions behind it.
What's inside your Recursion Pharmaceuticals report
Everything you need to decide — distilled from real, current user opinion.
Live mentions
The actual posts, reviews & complaints about Recursion Pharmaceuticals — with links and dates.
Honest verdict
A straight answer on whether it lives up to the hype — and who it’s really for.
Praise & gripes
What users genuinely love and the frustrations that keep coming up.
Real quotes
Representative voices from real users, not marketing copy.
Recurring themes
The patterns across hundreds of opinions, surfaced at a glance.
Red flags
Hidden costs and dealbreakers people only discover after signing up.
How it works
Sign up free
Create an account in seconds — get 5 free scans, no card.
We sweep the web
Live social media, forums, reviews & video opinions — in ~30–60s.
Get your report
An honest, downloadable verdict with the real mentions behind it.
Ready to see the real verdict on Recursion Pharmaceuticals?
Your scan is ready in under a minute · $1.
Top alternatives to Recursion Pharmaceuticals
Researching options? Explore the closest alternatives.
Insilico Medicine
Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.
Owkin
Owkin's K Pro is an autonomous AI scientist for drug discovery and clinical trial decisions, built on multimodal patient data
Recursion
Clinical-stage techbio company pairing automated wet labs with AI models to discover and develop drugs.
Insitro
Causal AI drug discovery that pairs 20+ petabytes of cellular data with human genetics to find real disease targets
Exscientia
Recursion's AI drug discovery platform pairing 2M weekly wet-lab experiments with a 50+ PB proprietary dataset, now incorporating Exscientia.
Evotec
Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.
Check sentiment on these too
Run a live scan on the alternatives before you decide.
Recursion Pharmaceuticals — questions buyers ask
What do people complain about most with Recursion Pharmaceuticals?
The complaints that recur most often are community discussion is almost entirely about the stock, not the platform or its scientific merit, retail shareholders repeatedly flag huge outstanding share count and ongoing executive selling and no licensable product means outside researchers and developers cannot evaluate the AI stack. Drawn from 19 mentions across 1 sources.
What do users like about Recursion Pharmaceuticals?
Users consistently praise REC-1245 Phase 1 data showed well-tolerated safety and predictable pharmacokinetics with no DLTs observed, clinical-stage pipeline gives the AI platform narrative concrete, checkable evidence points and genentech optioned the first neuroscience target in August 2026, validating the partnership model.
Is Recursion Pharmaceuticals hard to learn?
Users describe it as advanced; most people are up and running in days of setup; the usual sticking points are the platform isn't accessible to outsiders, so there's no 'getting started' as a user and understanding the company requires reading clinical trial data, not just product docs.
Who should not use Recursion Pharmaceuticals?
Based on what users report, it is a poor fit for developers or data scientists looking for a licensable AI drug discovery software product, researchers who need to run their own experiments on the platform, since it is internal only and investors seeking near-term revenue or low-volatility exposure.
What are people saying about Recursion Pharmaceuticals right now?
Discussion volume is low and trending down. Current topics: shkreli's short thesis on RXRX and his Godel Terminal promotion, share dilution and executive selling and REC-4881 Phase 2 data anticipation for FAP.
How current is this report?
Each scan runs live the moment you click — it reflects what people are saying now, and every report lists the dated mentions behind it.
Can I download it?
Yes — download the full report as a polished, shareable PDF.